ORZIPTA

Bristol-Myers Squibb Company

Application Filed: 2013-08-12

Trademark Application Details

Status

606

Dead/Abandoned

ABANDONED - NO STATEMENT OF USE FILED

Research	OneLook Acronym Finder
Serial Number	86034939
Mark Drawing Code	4000: Illustration: Drawing with word(s)/letter(s)/number(s) in Block form
Attorney Name	Marilyn F. Kelly
Law Office Assigned	M90
Employee Name	MCMORROW, RONALD G

Timeline

2013-08-12	Application Filed
2014-07-08	Published for Opposition
2016-03-24	Location: INTENT TO USE SECTION
2017-10-09	Abandon
2017-10-09	Status: Dead/Abandoned
2018-07-08	Transaction Date

Trademark Applicants & Owners

Owner:	Bristol-Myers Squibb Company
Address	345 Park Avenue New York DE 10154
Legal Entity Type	Corporation
Legal Entity State	DE

Documents

Click the blue "Refresh" button to load certificates, specimines, application, and other documents.

Attorney of Record

MARILYN F. KELLY
BRISTOL-MYERS SQUIBB COMPANY
PO BOX 4000
PRINCETON, NJ 08543-4000

Good, Services, and Codes

International Codes:	5
U.S. Codes:	006,018,044,046,051,052

Type Code	Type
GS0051	Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants and pharmaceutical antibodies

Type Code

Type

GS0051

Pharmaceutical preparations for human use for the treatment and prevention of obesity, diabetes, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection; pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants and pharmaceutical antibodies

Trademark Filing History

Description	Date	Event Coding
NEW APPLICATION ENTERED IN TRAM	2013-08-15	1 NWAP I:Incoming Correspondence
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM	2013-08-20	2 NWOS I:Incoming Correspondence
ASSIGNED TO EXAMINER	2013-11-14	3 DOCK D:Assigned to Examiner
NON-FINAL ACTION WRITTEN	2013-11-19	4 CNRT R:Renewal
NON-FINAL ACTION E-MAILED	2013-11-19	5 GNRT F:First Action
NOTIFICATION OF NON-FINAL ACTION E-MAILED	2013-11-19	6 GNRN O:Outgoing Correspondence
TEAS RESPONSE TO OFFICE ACTION RECEIVED	2014-05-13	7 TROA I:Incoming Correspondence
CORRESPONDENCE RECEIVED IN LAW OFFICE	2014-05-13	8 CRFA I:Incoming Correspondence
TEAS/EMAIL CORRESPONDENCE ENTERED	2014-05-13	9 TEME I:Incoming Correspondence
APPROVED FOR PUB - PRINCIPAL REGISTER	2014-05-15	10 CNSA P:
ASSIGNED TO LIE	2014-05-29	11 ALIE A:Allowance for Publication
LAW OFFICE PUBLICATION REVIEW COMPLETED	2014-06-03	12 PREV O:Outgoing Correspondence
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	2014-06-18	13 NONP E:E-Mail
PUBLISHED FOR OPPOSITION	2014-07-08	14 PUBO A:Allowance for Publication
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED	2014-07-08	15 NPUB E:E-Mail
NOA E-MAILED - SOU REQUIRED FROM APPLICANT	2014-09-02	16 NOAM E:E-Mail
TEAS EXTENSION RECEIVED	2015-02-05	17 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL	2015-03-19	18 AITU A:Allowance for Publication
EXTENSION 1 FILED	2015-02-05	19 EXT1 S:
EXTENSION 1 GRANTED	2015-03-19	20 EX1G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2015-03-20	21 EXRA E:E-Mail
TEAS EXTENSION RECEIVED	2015-08-20	22 EEXT I:Incoming Correspondence
EXTENSION 2 FILED	2015-08-20	23 EXT2 S:
EXTENSION 2 GRANTED	2015-09-03	24 EX2G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2015-09-04	25 EXRA E:E-Mail
TEAS EXTENSION RECEIVED	2016-02-24	26 EEXT I:Incoming Correspondence
CASE ASSIGNED TO INTENT TO USE PARALEGAL	2016-03-24	27 AITU A:Allowance for Publication
EXTENSION 3 FILED	2016-02-24	28 EXT3 S:
EXTENSION 3 GRANTED	2016-03-25	29 EX3G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2016-03-26	30 EXRA E:E-Mail
TEAS EXTENSION RECEIVED	2016-08-25	31 EEXT I:Incoming Correspondence
EXTENSION 4 FILED	2016-08-25	32 EXT4 S:
EXTENSION 4 GRANTED	2016-08-30	33 EX4G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2016-08-31	34 EXRA E:E-Mail
TEAS EXTENSION RECEIVED	2017-02-28	35 EEXT I:Incoming Correspondence
EXTENSION 5 FILED	2017-02-28	36 EXT5 S:
EXTENSION 5 GRANTED	2017-03-03	37 EX5G S:
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED	2017-03-04	38 EXRA E:E-Mail
ABANDONMENT - NO USE STATEMENT FILED	2017-10-09	39 ABN6 S:
ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED	2017-10-10	40 MAB6 O:Outgoing Correspondence

Similar Marks

Mark Image Registration \| Serial	Company Trademark Application Date
ORZIPTA 86034939 not registered Dead/Abandoned	Bristol-Myers Squibb Company 2013-08-12
ORZIPTA 78639785 not registered Dead/Abandoned	Bristol-Myers Squibb Company 2005-05-31
ORZIPTA 77789914 not registered Dead/Abandoned	Bristol-Myers Squibb Company 2009-07-27

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.